![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aprea Therapeutics Inc | NASDAQ:APRE | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.18 | -4.44% | 3.87 | 3.77 | 4.05 | 4.05 | 3.82 | 3.82 | 6,423 | 23:23:53 |
Details of the oral presentations are as follows:
Title: Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)Date & Time: Monday, December 9, 2019 at 11:15 am ETOral Abstract Session: 637. Myelodysplastic Syndromes—Clinical Studies: Targeting Gene Mutations in MDSAbstract: 676Location: Orange County Convention Center, W311ABCDPresenter: David A Sallman, M.D., Assistant Member, Malignant Hematology Department H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida
Title: APR-246 combined with Azacitidine (AZA) in TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). A phase 2 study by the Groupe Francophone des Myélodysplasies (GFM)Date & Time: Monday, December 9, 2019 at 11:30 am ETOral Abstract Session: 637. Myelodysplastic Syndromes—Clinical Studies: Targeting Gene Mutations in MDSAbstract: 677Location: Orange County Convention Center, W311ABCDPresenter: Thomas Cluzeau, M.D., Ph.D., Professor, Department of Clinical Hematology, Cote d’Azur University, Nice, France
Details of the Company’s Clinical Update meeting and webcast are as follows:
Time and Date: Monday, December 9 at 12:00 pm ETLocation: Hyatt Regency Orlando, Rainbow Spring 2 Room, 9801 International Drive, Orlando, FloridaWebcast: The Clinical Update meeting will be webcast live and can be accessed from "Events Calendar" in the News and Events section of the company's website at LinkPresentation: The presentation will be available as a PDF on the Company’s website at Link
About Aprea Therapeutics, Inc.
Aprea Therapeutics Inc., (NASDAQ: APRE) is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53. The Company’s lead product candidate is APR-246, a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Forward Looking Statements
This press release includes forward-looking statements within the meaning of the federal securities laws. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The forward-looking statements contained in this press release reflect Aprea’s current views with respect to future events, and Aprea does not undertake and specifically disclaims any obligation to update any forward-looking statements.
Corporate Contacts: Christian S. Schade President and Chief Executive Officer chris.schade@aprea.com Gregory A. Korbel, Ph.D. Vice President of Business Development greg.korbel@aprea.com
1 Year Aprea Therapeutics Chart |
1 Month Aprea Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions